Title:
Escitalopram for Agitation in Alzheimer's Disease
|
| What is the purpose of the study? |
| |
This study is designed to examine the efficacy and safety of escitalopram as treatment for agitation in Alzheimer's dementia (AD) patients. Participants will receive one on one counseling with a clinician to help decrease agitation. If after three weeks there is no improvement, they will be randomly assigned escitalopram or matching placebo. The study will last 24 weeks, and require individuals to come to CAMH with their caregivers for five visits. There will be telephone followup as needed.
|
| Who is needed? |
| |
Individuals with: |
Alzheimer's Disease, Agitation |
| |
Individuals without
a mental health or
addiction problem:
|
No
|
| |
Age range: |
over age 18 |
| |
Gender: |
All |
| |
Ethnicity: |
|
| |
Other:
|
|
| What does the study involve? |
| |
Number of contacts: |
5 in-person visits, phone follow up as needed |
| |
Time period: |
24 weeks |
| |
Length of contacts: |
2-4 hours for visits, phone calls 30 mins to 1 hour |
| |
Treatment offered:
|
Yes
|
Location:
|
1001 Queen St. West (Queen site), GMHS Research, Unit 4-380 Workman way, CAMH Cinical lab
|
Principal Investigator:
|
Tarek Rajji
|
| Contact information: |
| |
Phone: |
416-583-1350 |
| |
e-mail: |
scitad@camh.ca |
| |
Website: |
www.ad-trial.org |
| |
Flyer:
|
Download
|
Study end date:
|
01 Apr 2023
|
| REB number: |
019/2018 |
| Full study title: |
Escitalopram for Agitation in Alzheimer’s Disease (S-CitAD) |
| Keywords: |
Alzheimer's, Dementia, Agitation |
| Study Area: |
|
